A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma

International Journal of Hematology

Volumn 83, Issue 4, 2006, Pages 309-313

  Bang, Soo Mee ^a,o   Lee, Jae Hoon ^a   Yoon, Sung Soo ^b   Park, Seonyang ^b   Min, Chang Ki ^c   Kim, Chun Choo ^c   Suh, Cheolwon ^d   Sohn, Sang Kyun ^e   Min, Yoo Hong ^f   Lee, Je Jung ^g   Kim, Kihyun ^h   Seong, Chu Myong ⁱ   Yoon, Hwi Joong ^j   Cho, Kyung Sam ^j   Jo, Deog Yeon ^k   Lee, Kyung Hee ^l   Lee, Na Ri ^m   Kim, Chul Soo ⁿ  

^a Gachon University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Catholic HSCT Center   (South Korea)

^d Asan Medical Center   (South Korea)

^e Kyungpook National University Hospital   (South Korea)

^f Yonsei University   (South Korea)

^g Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ Ewha Womans University   (South Korea)

^j Kyung Hee University College of Medicine   (South Korea)

^k Chungnam National University College of Medicine   (South Korea)

^l Young Nam University Hospital   (South Korea)

^m Chonbuk National University Medical School   (South Korea)

ⁿ Inha University Hospital   (South Korea)

^o Seoul National University Bundang Hospital   (South Korea)

more..

Author keywords

Adverse events; Bortezomib; Multiple myeloma; Neurotoxicity; Thalidomide

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PROTEASOME INHIBITOR; THALIDOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FEVER; HUMAN; INCIDENCE; INFECTION; INSOMNIA; KOREA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; PAIN; PERIPHERAL NEUROPATHY; RASH; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SUICIDE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 33744489589     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A30512     Document Type: Article

References (19)

1. SH Yang, TY Kim, BK Kim, et al. A statistical study of multiple myeloma in Korea [in Korean]. Korean J Hematol. 1995;30: 345-361.
2. Ministry of Health and Welfare, Republic of Korea. Annual Report of Korean Cancer (2002.1-2002.12); 2004. Available at: http://www. ncc.re.kr.
3. Altal M, Harousseau JL, Stoppa AM, et al, for the Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
4. Bang SM, Cho EK, Suh C, et al. High dose therapy followed by autologous peripheral stem cell transplantation as a first line treatment for multiple myeloma: a Korean multicenter study. J Korean Med Sci. 2003;18:673-678.
5. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol. 2005;12:463-470.
6. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: 1565-1571.
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348:2609-2617.
8. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
9. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
10. Alexanian R, Wang LM, Weber DM, et al. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]. Blood. 2004;100(suppl 1):64a.
11. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-762.
12. Blade J, Samson D, Reece D, et al, on behalf of the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplantation), Chronic Leukaemia Working Party and the Myeloma Working committee of the IBMTR (International Bone Marrow Transplant Registry), and ABMTR (Autologous Blood and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
13. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2003. Available at: http://ctep.cancer.gov/ reporting/ctcnew.html. Accessed March 23.2006.
14. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106:3777-3784.
15. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol. 2005;18:574-580.
16. Richardson P, Briemberg H, Jagannath S, et al. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (Velcade®): the SUMMIT and CREST study group. In: Programs and Abstracts of the 9th Annual Congress of the European Hematology Association; June 11-13, 2004; Geneva, Switzerland. Abstract 368a.
17. Lee KW, Yun T, Song EK, et al. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma. J Korean Med Sci. 2005;20:598-602.
18. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials [abstract]. J Clin Oncol. 2005;23(suppl 1):6501a.
19. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma [abstract]. J Clin Oncol. 2005;23(suppl 1):6533a.